277 ORAL Interim results of a phase II randomized study of lapatinib (GW572016) as first-line treatment for patients with FISH-amplified advanced or metastatic breast cancer
2005 ◽
Vol 3
(2)
◽
pp. 78
◽
Keyword(s):
Phase Ii
◽